ConductScience.org, home

Comparison · NCT04334148-93280918

Hydroxychloroquine vs Placebo: Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hydroxychloroquine vs Placebo: Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs). Trial comparisons, record NCT04334148-93280918. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04334148-93280918

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01020.004970.021wilson
Risk in group 20.01180.006010.0232wilson
Risk difference, group 1 minus group 2-0.00159-0.01410.0106newcombe hybrid score
Risk ratio, group 1 over group 20.8660.3162.37log
Odds ratio, group 1 over group 20.8650.3122.4log
Number needed to treat, for one fewer participant with the outcome on Hydroxychloroquine than on Placebo631from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1HydroxychloroquineHydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.~Hydroxychloroquine: oral self administered tablet7683OG000
Group 2PlaceboMatching placebo tablets~Placebo oral tablet: oral self administered tablet8676OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)
Description
Safety and Tolerability as determined by subject reported serious adverse events (SAEs) and hydroxychloroquine-associated events of special interest. EOSIs include: arrhythmias (ventricular), hepatic failure, bone marrow failure, aplastic anemia, prolonged QT interval, angioedema, dermatitis exfoliative, acute generalized exanthematous pustulosis, psychosis, suicidal ideation, seizure, methemoglobinemia.
Time frame
30 days
Population
Participants who completed the study.

Source ClinicalTrials.gov

Trial

Title
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
NCT number
NCT04334148
Phases
PHASE3
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Lead sponsor
Adrian Hernandez
Results first posted
2021-10-07

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04334148-93280918